Altria Group Inc

Altria generates revenue primarily through manufacturing and selling cigarettes, including its dominant Marlboro brand, along with smokeless tobacco and oral nicotine products. The company operates exclusively in the United States, making money from sales to retailers and distributors. Altria has invested in reduced-risk products including oral nicotine pouches and holds equity stakes in Anheuser-Busch InBev and cannabis company Cronos. The business model relies on brand strength and pricing power despite declining cigarette volumes.

Altria offers a high dividend yield exceeding 6% supported by strong cash generation from its cigarette business. The company benefits from pricing power that offsets volume declines as smoking rates decrease. Strengths include the Marlboro brand dominance and diversification efforts. Risks include continued regulatory pressures, litigation exposure, accelerating cigarette volume declines, execution challenges in reduced-risk products, and ESG concerns limiting institutional ownership. The stock typically trades at discounted valuations reflecting secular headwinds.

Altria competes with British American Tobacco, which owns the Reynolds American brands including Camel and Newport in the U.S. market. Imperial Brands operates in combustibles and next-generation products. In smokeless and oral nicotine, Altria competes with Swedish Match (now owned by Philip Morris International) and Zyn, which has captured significant market share in nicotine pouches. The companies compete intensely on pricing, product innovation, and retailer relationships.

Altria pays a quarterly dividend yielding approximately 6.48%, among the highest yields in the market, making it popular with income investors. The company has a long history of dividend increases, though growth has slowed as management balances payouts with investments in alternative products. Altria's dividend is well-covered by cash flow from cigarette sales despite declining volumes, supported by pricing increases and cost management. The high yield compensates investors for regulatory and secular risks facing the tobacco industry.

MO last closed at $63.78, down 0.84% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $52.82 and a high of $70.51. The current price represents 62% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 24 analysts covering MO, the consensus rating is Hold — 13 rate it a buy, 8 hold, and 3 sell. The average price target sits at $104.13, implying 63% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Altria Group Inc generated $23.13B in revenue during fiscal year 2026, with $6.90B reaching the bottom line as net income. The net profit margin of 29.8% is strong by most industry standards.

MO trades at a P/E ratio of 15.52 on trailing earnings of $4.13 per share. That's roughly in line with the broader market average of ~20-25x. Comparing this multiple against Tobacco sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: +10.73% (3M), -2.88% (6M), +10.44% (1Y), +11.29% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether MO is outperforming or lagging the broader market.